22:58 , Jul 10, 2019 |  BC Extra  |  Company News

Management tracks: Maze, Tiaki, NED, Annexon and more

Maze Therapeutics (Redwood City, Calif.) said Richard Scheller joined its board. Scheller, who in January became chairman of R&D at BridgeBio Pharma Inc. (NASDAQ:BBIO), was CSO and head of therapeutics at personal genetics company 23andMe...
07:00 , Oct 31, 2016 |  BC Week In Review  |  Financial News

QR Pharma completes venture financing

QR Pharma Inc. , Berwyn, Pa.  Business: Neurology  Date completed: 2016-10-27  Type: Venture financing  Raised: $800,000  Investors: Robin Hood Ventures; angel investors ...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Financial News

QR Pharma completes venture financing

QR Pharma Inc. , Berwyn, Pa.   Business: Neurology   Date completed: 2015-05-26   Type: Venture financing   Raised: $1.1 million   Investors: Robin Hood Ventures; angel investors; company director   Note: The company also...
08:00 , Mar 2, 2015 |  BC Week In Review  |  Company News

QR Pharma, Rockefeller University deal

QR Pharma partnered with the university for preclinical testing of QR’s Posiphen for Huntington’s disease. Rockefeller will use stem cell culture models to determine if Posiphen lowers the levels of the huntingtin protein, promotes differentiation...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Company News

QR Pharma, University of California neurology news

QR Pharma and the university received a $3 million grant from the U.S. Army to test Posiphen in rat models to treat traumatic brain injury (TBI). The partners will continue to conduct preclinical studies of...
07:00 , Jul 30, 2012 |  BC Week In Review  |  Clinical News

Bisnorcymserine: Phase I started

QR Pharma began a double-blind Phase I trial to evaluate single ascending-doses of 20, 40, 80, 160, 380, 490 and 600 mg bisnorcymserine in up to 56 healthy elderly volunteers. The company has exclusive, worldwide...
07:00 , Mar 12, 2012 |  BC Week In Review  |  Company News

QR Pharma, Michael J. Fox Foundation For Parkinson's Research neurology news

QR Pharma received a $468,000 grant from the foundation to develop Posiphen to treat Parkinson's disease. QR Pharma will conduct preclinical studies of the amyloid precursor protein (APP) translation inhibitor in a mouse model of...
07:00 , Oct 24, 2011 |  BioCentury  |  Product Development

Alzheimer's rewind

A string of Phase II and III failures in Alzheimer's disease has prompted companies to look for new targets beyond the well-known players in the core mechanism of AD - the production and accumulation of...
07:00 , May 30, 2011 |  BioCentury  |  Emerging Company Profile

QR: Power of positivity

QR Pharma Inc. has in-licensed a pair of compounds for cognitive impairment and Alzheimer's disease it believes have suffered from neglect rather than a lack of efficacy or safety. The more advanced of the two...
07:00 , Jun 7, 2010 |  BC Week In Review  |  Financial News

QR Pharma completes venture financing

QR Pharma Inc. , Radnor, Pa.   Business: Neurology   Date completed: 6/2/10   Type: Venture financing   Raised: $2.5 million   Investors: BioAdvance; Ben Franklin Technology Partners; angel investors; private investors  ...